ArticleBMC medicine2026
Global immunisation planning and economic development potential: a panel data analysis for the macroeconomic impact of hepatitis B vaccination from 2000 to 2018.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe Immunisation Agenda 2030, led by the World Health Organisation (WHO), outlines a ten-year strategy to ensure universal access to vaccines worldwide to improve health and well-being. The hepatitis B virus (HBV) vaccine, included in the Global Alliance for Vaccines and Immunisation (Gavi) pentavalent vaccine, has been successfully introduced in many low-income countries since 2000. Despite its recognised cost-effectiveness in enhancing health capital, the economic pathways through which vaccination rate affects development remain underexplored. This study aims to examine the effect of vaccination rate on gross domestic product (GDP) growth and its underlying mechanisms after the launch of Gavi.
methodsData were mainly obtained from WHO, World Development Indicators (WDI), Penn World Table 10.0 (PWT 10.0), WHO and UNICEF Estimates for National Immunisation Coverage (WUENIC). A conditional convergence model was used to evaluate the association between the three-dose vaccine of HBV (HBV3) vaccination rate and GDP growth from 2000 to 2018 across countries. Guided by Grossman's health capital theory, the study further explored mediation pathways via the under-5 mortality rate and the number of persons engaged. Income-group-based heterogeneity analyses were also conducted.
resultsHBV3 vaccination rates rose globally during the study period, with the rate gap across income groups narrowing from over 20% to around 10%. A 1% increase in HBV3 vaccination rate was associated with a 1.17% GDP per capita convergence rate per year (p < 0.01). Vaccination rate was negatively associated with the under-5 mortality rate (β=-0.104, p < 0.01) and positively with the number of persons engaged (β = 6.935, p < 0.01), though mediation was only partial. Heterogeneity analyses by income group revealed that the economic impact of vaccination rate was significantly concentrated (β = 0.0164, p < 0.01) in lower-middle-income countries (LMICs).
conclusionsThese findings suggest that improved HBV3 vaccination rate promotes GDP growth through enhanced health capital, especially in LMICs. Therefore, sustained investments in routine immunisation are crucial for maximising economic and health returns and addressing vaccine inequities. However, the limitations of the analytical framework and data accessibility hinder solid conclusions regarding the long-term economic impacts driven by delayed health benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.